SECsense Logo

Cara Therapeutics, Inc. 8-K Report: Key Updates & Insights as of Dec 17, 2024

$CARA
Form 8-K
Filed on: 2024-12-18
Source
Cara Therapeutics, Inc. 8-K Report: Key Updates & Insights as of Dec 17, 2024

Based on the provided section of the financial report for Cara Therapeutics, Inc., here are the key pieces of information extracted:

  1. Entity Information:
  • Company Name: Cara Therapeutics, Inc.
  • CIK: 0001346830
  • Jurisdiction: Delaware (DE)
  • SEC File Number: 001-36279
  • EIN: 75-3175693
  • Address: 400 Atlantic Street, Suite 500, Stamford, CT 06901
  • Phone Number: 203-406-3700
  1. Filing Type:
  • Form Type: 8-K (reporting unscheduled material events or corporate changes)
  1. Filing Date:
  • Date of Report: December 17, 2024
  1. Stock Information:
  • Common Stock: Par value of $0.001 per share
  • Ticker Symbol: CARA
  • Exchange: NASDAQ
  1. Financial Context:
  • Reporting Period: As of December 17, 2024 (the start and end date are the same, indicating this is a snapshot reporting).
  • Currency: USD (United States Dollar)
  • Measurement Units: Financial metrics are presented in both USD and shares.

Insights:

  • The filing is a current report (8-K), which typically indicates that the company is disclosing important or material information that could influence the company’s stock price or investor decisions.
  • The mention of common stock with a par value suggests that the company might be involved in stock-related corporate actions, such as issuing new shares or stock splits.
  • The report is recent, dated just a few days before it was filed, indicating a prompt disclosure of current events.

This information can be crucial for investors and analysts monitoring Cara Therapeutics, especially in evaluating any potential changes in the company's financial standing or corporate structure.